Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3300+0.0350 (+2.70%)
As of 01:02PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 4.34M
Enterprise value 3.39M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.01
Price/book (mrq)1.79
Enterprise value/revenue 0.79
Enterprise value/EBITDA -0.48

Trading information

Stock price history

Beta (5Y monthly) 0.27
52-week change 3-21.81%
S&P500 52-week change 312.18%
52-week high 35.9600
52-week low 30.9190
50-day moving average 31.2329
200-day moving average 31.7182

Share statistics

Avg vol (3-month) 313.87k
Avg vol (10-day) 318.1k
Shares outstanding 53.34M
Implied shares outstanding 63.34M
Float 83.25M
% held by insiders 12.46%
% held by institutions 12.07%
Shares short (14 Nov 2023) 422.52k
Short ratio (14 Nov 2023) 42.73
Short % of float (14 Nov 2023) 40.69%
Short % of shares outstanding (14 Nov 2023) 40.67%
Shares short (prior month 12 Oct 2023) 430.25k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 322 May 2022

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin -176.89%
Operating margin (ttm)-102.60%

Management effectiveness

Return on assets (ttm)-42.64%
Return on equity (ttm)-326.59%

Income statement

Revenue (ttm)4.3M
Revenue per share (ttm)1.29
Quarterly revenue growth (yoy)87.80%
Gross profit (ttm)2.14M
Net income avi to common (ttm)-7.61M
Diluted EPS (ttm)-2.2700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.96M
Total cash per share (mrq)1.78
Total debt (mrq)5.01M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.50
Book value per share (mrq)-0.26

Cash flow statement

Operating cash flow (ttm)-6.39M
Levered free cash flow (ttm)-4.12M